GPGrossPatternRESEARCH SYSTEM
SEC CHECK OPERATIONAL
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

SRCE · Mar 31, 2025

1ST SOURCE CORP. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration

State dimensions

Filing0000034782-25-000045Bank
Sequential deposit growth75thOwn-history percentile · N=20
Evidence method

Sequential · gp.financial.deposits

2.60% · CORE · VALID

Net-income growth80thOwn-history percentile · N=20
Evidence method

Yoy · gp.fundamentals.net_income

27.36% · CORE · VALID

Interest-income growth40thOwn-history percentile · N=20
Evidence method

Yoy · gp.financial.interest_income

5.87% · CORE · VALID

Cash and equivalents60thOwn-history percentile · N=20
Evidence method

Level · gp.fundamentals.cash

$222.8M · CORE · VALID

Sequential loan growth30thOwn-history percentile · N=20
Evidence method

Sequential · gp.financial.loans

0.10% · CORE · VALID

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History60 statesSelf-history eligible
Period transition

What moved in the state?

Deposit Growth Increased
Previous
1.46%
Current
2.60%
Delta
1.14%
Earnings Growth Increased
Previous
6.15%
Current
27.36%
Delta
21.21%
Interest Income Growth Decreased
Previous
16.10%
Current
5.87%
Delta
-10.23%
Liquidity Increased
Previous
$124.8M
Current
$222.8M
Delta
$98.0M
Loan Growth Decreased
Previous
3.64%
Current
0.10%
Delta
-3.54%
Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.
Research Graph

Related governed research

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.